Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
April 18, 2016 9:59 AM EDTStifel analyst, Thomas Shrader, thinks that preclinical excitement for Medivation's (NASDAQ: MDVN) talazoparib is bearing fruit. Much of Medivations excitement in Talazoparib is based on the drugs ability to trap the PARP enzyme on the DNA and act like a Topo II inhibitor in addition to inhibiting PARP enzymatic activity. Topo II inhibitors from the anthracycline family are the most broadly active drugs... More
